Universal remedy against various types of cancer received approval

Office on the US Food and Drug Administration (FDA) approved the production of a new universal drug Vitrakvi anti-cancer drugs developed by Loxo Oncology in collaboration with Bayer. A feature of the drug is that it is designed to deal with mutations in cancerous tumors at the genetic level. The technique can be used to treat any type of cancer - the value has only a type of genetic distortion, and not the location of the cancer. This publication reports Business Insider.

Universal remedy against various types of cancer received approval

Medicine expensive. Vitrakvi year's supply will cost 393 thousand dollars. In a statement, Bayer said that every year from 2500-3000 people are diagnosed genetic mutations that lead to the development of cancerous tumors. It also reported that the drug for children will be in liquid form, and the price for this annual event will be reduced to 132 thousand dollars a year. Bayer also said that going to offer financial assistance to those patients who can not pay the full cost of the drug. In this case, the price for them will be significantly reduced - the cost of a monthly stock Vitrakvi will be $ 20, which is quite feasible for most patients.

"Today's approval is another important step in the fight against various types of cancer based on their tumor genetics, not just on the basis of their local origin in the body", - reported on the website of the Office of the Food and Drug US funds.

In 2017 Loxo Oncology signed with pharmaceutical giant Bayer agreement on the 1, 5 billion dollars to develop and bring to market two commercial drugs Loxo, including Vitrakvi. In trials of this drug called larotrektinib (larotrectinib LOXO-101).

Using the funds allocated to specific genetic mutations, is a new approach in the treatment of cancer. Most pharmaceutical companies are developing drugs designed only for the treatment of a certain type of cancer, such as lung cancer or melanoma. In this case it is necessary each time to obtain the approval of regulatory authorities to test the effects of these drugs on other types of cancer.

Deciphering the genetic pattern of tumor it is often used in modern medicine. However, this approach has attracted a lot of attention only in 2013, when scientists found that the endometrial cancer has a similar genetic picture of ovarian cancer and breast. In May 2017 the FDA approved the first drug aimed at the treatment of genetic mutations, which paved the way for the development of similar devices by other manufacturers, including Loxo. The new drug Loxo Oncology affects a certain type of mutation - TRK-fused gene. It leads to the development of various types of cancer: sarcoma, thyroid cancer, non-small cell lung cancer and other types.

The tests of the drug in humans have shown positive results. At the last meeting of the European Society for Medical Oncology Loxo Oncology said that among the 109 patients treated with this drug in studies, 81 percent of the total observed a positive trend in the treatment - the size of cancerous tumors decreased. At the same time 17 percent of the patients experienced a complete positive response - a cancerous tumor completely receded from their body.

Discuss the news may be in our Telegram-chat.